ClinicalTrials.gg
Not yet recruitingNCT06837584Updated Feb 17, 2026

Control and Treatment of Outpatient Children With Asthma

An observational study in Asthma, sponsored by Beijing Children's Hospital. Not yet recruiting. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Beijing Children's Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
42,000
Ages
2 Years to 18 Years
Sex
All
01

Study summary

The aim of this study is to comprehensively understand the disease control and management status of children with asthma in China, as well as the types of airway inflammation. The findings of this survey will help improve the asthma control level in Chinese children, facilitate future patient education, and guide rational medication use. Moreover, it will provide important evidence for health decision-making departments to better allocate and utilize medical resources.

Read the detailed description

Bronchial asthma (hereinafter referred to as asthma) is the most common chronic respiratory disease in children. It severely affects the physical and mental health of children and imposes a huge economic burden on families and society, consuming a large amount of medical and health resources. In recent years, the prevalence of asthma in children worldwide has generally continued to rise. Data from the Global Burden of Disease database in 2019 showed that the prevalence of asthma in children aged 0-9 years was 4.21%, in children aged 10-14 years was 4.10%, and in adolescents aged 15-19 years was 3.00%. In China, over the past 20 years, the prevalence of asthma in children has also shown an overall upward trend, increasing from 0.91% in 1990 to 1.54% in 2000, and then to 3.02% in 2010. Thanks to the continuous efforts of several generations of pediatricians, the level of standardized diagnosis and treatment of childhood asthma has significantly improved. However, the control of asthma in children still faces many challenges.

The purpose of this study is to comprehensively understand the disease control and management status of children with asthma in China, as well as the types of airway inflammation. The findings of this survey will help improve the asthma control level in Chinese children, facilitate future patient education, guide rational medication use, and provide important evidence for health decision-making departments to better allocate and utilize medical resources.

02

Conditions studied

  • Asthma

Browse trials for

Keywords

  • asthma
  • children
  • outpatients
  • management
  • control
03

In context

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

This study's planned enrollment of 42,000 is above the median of 159 across 1,254 observational studies indexed under Asthma.

Browse Asthma studies →

Lead sponsor

Beijing Children's Hospital is the lead sponsor of 52 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Children aged 2-18 years and diagnosed with asthma ≥3 months were enrolled in the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 2 and 18 years old
  • Diagnosed with asthma for more than 3 months
  • Had asthma symptoms or asthma treatment within the past 12 months.

Exclusion criteria

Exclusion Criteria:

  • With other respiratory diseases such as bronchiectasis, bronchiolitis, cystic fibrosis, and pneumonia
  • Have participated in any interventional clinical studies related to asthma within the 3 months prior to enrollment in this study
  • Parents, legal representatives, or guardians do not agree to participate in this study.
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
42,000 participants (estimated)
Patient registry
No

Interventions

  • OtherQuestionnaire and Physical Exam

    Questionnaire and Physical Exam

06

What researchers measure

Primary outcomes

  1. Asthma control level

    The Asthma Control Test (ACT) will be employed for assessment, with the following interpretation criteria: a total score of 20-25 indicates well-controlled asthma, where symptoms are satisfactorily managed and the current treatment regimen should be continued; a score of 16-19 suggests poorly controlled asthma, indicating suboptimal symptom management that requires treatment adjustment or enhanced disease management; and a score of 5-15 reflects very poorly controlled asthma, with severe uncontrolled symptoms necessitating immediate medical attention and treatment modification.

    Time frame: 3 months before and at the time of enrollment

  2. The proportion of type 2 inflammation

    Blood EOS and IgE were used to judge. The T2 inflammatory phenotypes were classified based on blood eosinophil count and total specific IgE levels: Only-atopy was defined as blood eosinophils \<300/μL with sum of all specific IgE ≥0.7 kU/L; Only-EOS as blood eosinophils ≥300/μL with sum of all specific IgE \<0.7 kU/L; T2-high as blood eosinophils ≥300/μL with sum of all specific IgE ≥0.7 kU/L; and T2-low as blood eosinophils \<300/μL with sum of all specific IgE \<0.7 kU/L.

    Time frame: 3 months before and at the time of enrollment

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2026; primary completion for Oct 2026, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2025
First posted
Feb 20, 2025
StartEst.
Apr 1, 2026
Primary completionEst.
Oct 1, 2026
CompletionEst.
Dec 1, 2027
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06837584
Lead sponsor
Beijing Children's Hospital
Responsible party
Kunling Shen (Professior, Shenzhen Children's Hospital) — Principal investigator
First posted
Feb 20, 2025
Start date
Apr 1, 2026 (estimated)
Primary completion
Oct 1, 2026 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Feb 17, 2026

Study contacts

Peng Han, Doctor
Contact
hanpengonly1@163.com
+86-18612935979

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion